Ulrika Maria Wennberg

Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden.

Jederstrom Pharmaceuticals is a life sciences company that is developing new formulations for oral delivery of therapeutic proteins. These new formulations offer new and improved therapeutic possibilities, cost advantages and the convenience factor of oral administration. The vision of Jederstrom Pharmaceuticals is to make oral administration the method of choice for a number of key therapeutic proteins. Jederstrom Pharmaceuticals initial focus is to develop an insulin formulation for oral administration. Formulations of other well-known therapeutic proteins will then be developed. Jederstrom Pharmaceuticals' business model shall be out licensing. Jederstrom Pharmaceuticals was founded in 2001 by Gustaf Jederström, inventor of the formulation technology. Gustaf Jederström has more than 30 years experience of R&D in the pharmaceutical industry, where he has been instrumental in bringing numerous new pharmaceutical products to market.

Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden.

Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden.

Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden.

Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden.

Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden.

Jederstrom Pharmaceuticals is a life sciences company that is developing new formulations for oral delivery of therapeutic proteins. These new formulations offer new and improved therapeutic possibilities, cost advantages and the convenience factor of oral administration. The vision of Jederstrom Pharmaceuticals is to make oral administration the method of choice for a number of key therapeutic proteins. Jederstrom Pharmaceuticals initial focus is to develop an insulin formulation for oral administration. Formulations of other well-known therapeutic proteins will then be developed. Jederstrom Pharmaceuticals' business model shall be out licensing. Jederstrom Pharmaceuticals was founded in 2001 by Gustaf Jederström, inventor of the formulation technology. Gustaf Jederström has more than 30 years experience of R&D in the pharmaceutical industry, where he has been instrumental in bringing numerous new pharmaceutical products to market.

Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden.

Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden.

Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden.

Jederstrom Pharmaceuticals is a life sciences company that is developing new formulations for oral delivery of therapeutic proteins. These new formulations offer new and improved therapeutic possibilities, cost advantages and the convenience factor of oral administration. The vision of Jederstrom Pharmaceuticals is to make oral administration the method of choice for a number of key therapeutic proteins. Jederstrom Pharmaceuticals initial focus is to develop an insulin formulation for oral administration. Formulations of other well-known therapeutic proteins will then be developed. Jederstrom Pharmaceuticals' business model shall be out licensing. Jederstrom Pharmaceuticals was founded in 2001 by Gustaf Jederström, inventor of the formulation technology. Gustaf Jederström has more than 30 years experience of R&D in the pharmaceutical industry, where he has been instrumental in bringing numerous new pharmaceutical products to market.

Jederstrom Pharmaceuticals is a life sciences company that is developing new formulations for oral delivery of therapeutic proteins. These new formulations offer new and improved therapeutic possibilities, cost advantages and the convenience factor of oral administration. The vision of Jederstrom Pharmaceuticals is to make oral administration the method of choice for a number of key therapeutic proteins. Jederstrom Pharmaceuticals initial focus is to develop an insulin formulation for oral administration. Formulations of other well-known therapeutic proteins will then be developed. Jederstrom Pharmaceuticals' business model shall be out licensing. Jederstrom Pharmaceuticals was founded in 2001 by Gustaf Jederström, inventor of the formulation technology. Gustaf Jederström has more than 30 years experience of R&D in the pharmaceutical industry, where he has been instrumental in bringing numerous new pharmaceutical products to market.

Jederstrom Pharmaceuticals is a life sciences company that is developing new formulations for oral delivery of therapeutic proteins. These new formulations offer new and improved therapeutic possibilities, cost advantages and the convenience factor of oral administration. The vision of Jederstrom Pharmaceuticals is to make oral administration the method of choice for a number of key therapeutic proteins. Jederstrom Pharmaceuticals initial focus is to develop an insulin formulation for oral administration. Formulations of other well-known therapeutic proteins will then be developed. Jederstrom Pharmaceuticals' business model shall be out licensing. Jederstrom Pharmaceuticals was founded in 2001 by Gustaf Jederström, inventor of the formulation technology. Gustaf Jederström has more than 30 years experience of R&D in the pharmaceutical industry, where he has been instrumental in bringing numerous new pharmaceutical products to market.

Jederstrom Pharmaceuticals is a life sciences company that is developing new formulations for oral delivery of therapeutic proteins. These new formulations offer new and improved therapeutic possibilities, cost advantages and the convenience factor of oral administration. The vision of Jederstrom Pharmaceuticals is to make oral administration the method of choice for a number of key therapeutic proteins. Jederstrom Pharmaceuticals initial focus is to develop an insulin formulation for oral administration. Formulations of other well-known therapeutic proteins will then be developed. Jederstrom Pharmaceuticals' business model shall be out licensing. Jederstrom Pharmaceuticals was founded in 2001 by Gustaf Jederström, inventor of the formulation technology. Gustaf Jederström has more than 30 years experience of R&D in the pharmaceutical industry, where he has been instrumental in bringing numerous new pharmaceutical products to market.

Jederstrom Pharmaceuticals is a life sciences company that is developing new formulations for oral delivery of therapeutic proteins. These new formulations offer new and improved therapeutic possibilities, cost advantages and the convenience factor of oral administration. The vision of Jederstrom Pharmaceuticals is to make oral administration the method of choice for a number of key therapeutic proteins. Jederstrom Pharmaceuticals initial focus is to develop an insulin formulation for oral administration. Formulations of other well-known therapeutic proteins will then be developed. Jederstrom Pharmaceuticals' business model shall be out licensing. Jederstrom Pharmaceuticals was founded in 2001 by Gustaf Jederström, inventor of the formulation technology. Gustaf Jederström has more than 30 years experience of R&D in the pharmaceutical industry, where he has been instrumental in bringing numerous new pharmaceutical products to market.

Jederstrom Pharmaceuticals is a life sciences company that is developing new formulations for oral delivery of therapeutic proteins. These new formulations offer new and improved therapeutic possibilities, cost advantages and the convenience factor of oral administration. The vision of Jederstrom Pharmaceuticals is to make oral administration the method of choice for a number of key therapeutic proteins. Jederstrom Pharmaceuticals initial focus is to develop an insulin formulation for oral administration. Formulations of other well-known therapeutic proteins will then be developed. Jederstrom Pharmaceuticals' business model shall be out licensing. Jederstrom Pharmaceuticals was founded in 2001 by Gustaf Jederström, inventor of the formulation technology. Gustaf Jederström has more than 30 years experience of R&D in the pharmaceutical industry, where he has been instrumental in bringing numerous new pharmaceutical products to market.